Benefit of nephron sparing surgery translates into lower cancer specific mortality in patients with localized renal cell carcinoma

National Comprehensive Centre Network (NCCN) (1), as well as European Association of Urology (EAU) (2) guidelines recommend partial nephrectomy (PN) as the treatment of choice for stage T1 renal cell carcinoma (RCC). This recommendation is based on the rationale for maximal renal function preservation, lower risk of cardiovascular events and lower rate of other-cause mortality (OCM) provided by PN, relative to radical nephrectomy (RN) (3-7). Additionally, PN provides equivalent cancer control rates, relative to RN (8).